Use of immunoglobulin against hepatitis B to prevent this infection

  • Authors: Mukomolov S.L1, Mikhailov M.I2
  • Affiliations:
    1. Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
    2. M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Medical Sciences
  • Issue: No 1 (2014)
  • Pages: 47-54
  • Section: Articles
  • URL: https://journals.eco-vector.com/2226-6976/article/view/277352
  • ID: 277352

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

For the specific prevention of hepatitis B (HB), it is advisable to use purified HB virus surface antigen (HBsAg)-based vaccines to form active immunity and HB immunoglobulin (HBIG) containing the high concentrations of antibodies to anti-HBsAg (anti-HBs). Active/passive immunization that contemplates the simultaneous administration of HBIG and HB vaccine is a preferred variant of emergency prevention of HB. This approach should be applied when there is a high probability of percutaneous HB virus inoculation after prick with a blood-contaminated needle or another sharp instrument; after bite or another skin injury; when there is a high risk of transmission across the mucosae, for example when infected blood gets on the conjunctiva and other mucosae; there is a risk of sexual transmission during unprotected heterosexual or homosexual contact; there is a high risk of transmission from the virus-carrying mother (who is ill with chronic HB) to her neonatal baby; for the prevention of recurrent HB after liver transplantation with or without specific antiviral drugs, as well as in those who are unresponsive to HB vaccination if there has been a likely contact with HB virus.

Full Text

Restricted Access

About the authors

S. L Mukomolov

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare

Email: s.mukomolov@mail.ru

M. I Mikhailov

M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Medical Sciences

Email: michmich2@yandex.ru

References

  1. Reesink H.W., Duimel W.J., de Boer J.E., van Elven E.H., Brummelhuis H.G. The use of hepatitis B immunoglobulin in the Netherlands. Dev. Biol. Stand. 1975; 30: 310-315.
  2. Scheiermann N., Kuwert E.K. Uptake and elimination of hepatitis B immunoglobulins after intramuscular application in man. Dev. Biol. Stand. 1983; 54: 347-355.
  3. Wahl M., Hermodsson S., Kjellman H., Iwarson S. Recovery and turnover rate of hepatitis B immunoglobulin in volunteers. Dev. Biol. Stand. 1983; 54: 341-345.
  4. Немечек В., Часткова Ю., Гелцл Ю. Пассивная иммунизация чехословацким гипериммунным иммуноглобулином (HBIG) Hepaga. В кн.: Вирусные гепатиты. М.-Прага, 1985; 183-186.
  5. Лох Т., Бжоско В.Б., Цянцара Я., Баршч Т., Кацперска Э. Профилактика заражения вирусом гепатита В новорожденных от матерей-носителей HBsAg с помощью анти-HBs иммуноглобулина. В кн.: Вирусные гепатиты. Ташкент, 1985; 117-122.
  6. Maynard J.E. Passive immunization against hepatitis B: a review of recent studies and comment on current aspects of control. Am. J. Epidemiol. 1978; 107(2): 77-86.
  7. Prince A.M., Szmuness W., Mann M.K., Vyas G.N., Grady G.F., Shapiro F.L. et al. Hepatitis B immune globulin: effectiveness in prevention of dialysis-associated hepatitis. N. Engl. J. Med. 1975; 293(21): 1063-1067.
  8. Prince A.M., Szmuness W., Mann M.K., Vyas G.N., Grady G.F., Shapiro F.L. et al. Hepatitis B immune globulin: final report of a controlled, multicenter trial of efficacy in prevention of dialysis-associated hepatitis. J. Infect. Dis. 1978;137(2): 131-144.
  9. Winsnes R., Siebke J.C. Efficacy of post-exposure prophylaxis with hepatitis B immunoglobulin in Norway. J. Infect. Dis. 1986; 12(1): 11-21.
  10. Palmovic D. Prevention of hepatitis B infection in health care workers after accidental exposure. J. Infect. Dis. 1987; 15(3): 221-224.
  11. Shao Z-J., Zhang L., Xu J-Q., Xu De-Z., Men K., Zhang J-X. et al. Mother to infant transmission of Hepatitis B virus: a Chinese experience. J. Med. Virol. 2011; 83: 791-795.
  12. Minuk G.Y., Bohme C.E., Bowen T.J. Passive and active immunization against hepatitis B virus infection: optimal scheduling in healthy young adults. Clin. Invest. Med. 1989; 12(3): 175-180.
  13. Mitsui T., Iwano K., Suzuki S., Yamazaki C., Masuko K., Tsuda F. et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in histirical controls. Hepatology 1989; 10(3): 324-327.
  14. Pezzella M., Galli C., Zennaro F., Giananni-Corradini S. Costs and benefits of the passive prophylaxis of hepatitis B in an Italian hospital. Int. J. Epidemiol. 1985; 14(3): 453-456.
  15. Beasley R.P., Hwang L.Y., Stevens C.E., Lin C.C., Hsieh F.J., Wang K.Y. et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983; 3(2): 135-141.
  16. Beasley R.P., Hwang L.Y., Szmuness W., Stevens C.E., Lin C.C., Hsieh F.J. et al. HBIG prophylaxis for prevention HBV-infection - final report of the Taiwan trial. Dev. Biol. Stand. 1983; 54: 363-375.
  17. Beasley R.P., Hwang L.Y., Lee G.C., Lan C.C., Roan C.H., Huang F.Y., Chen C.L. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2( 8359): 1099-1102.
  18. Junqueira A.L.N., Tavares V.R., Martins R.M.B., Frauzino K.V., da Costa e Silva A.M., Rodrigues I.M.X. et al. Presence of maternal anti-HBs does not influence hepatitis B vaccine response in Brazilian neonates. Mem. Inst. Oswaldo Cruz. 2011; 106(1): 113-116.
  19. Wong V.C., Ip H.M., Reesink H.W., Lelie P.N., Reerink-Brongers E.E., Yeung C.Y., Ma H.K. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; 1(8383): 921-926.
  20. Lo K.J., Tsai Y.T., Lee S.D., Yeh C.L., Wang J.Y., Chiang B.N. et al. Combined passive and active immunization for interraption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology 1985; 32(2): 65-68.
  21. Lo K.J., Tsai Y.T., Lee S.D., Wu T.S., Wang J.Y., Chen G.H. et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J. Infect. Dis. 1985; 152(4): 817-822.
  22. Esteban J.I., Genesca J., Esteban R., Hernandez J.M. Seijo G., Buti M. et al. Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. J. Med. Virol. 1986; 18(4): 381-391.
  23. Kanai K., Takehiro A., Noto H., Nishida M., Takahashi K., Kawashima Y. et al. Prevention of perinatal transmission of hepatitis B virus (HBV) to children of e antigen-positive HBV carrier mothers by hepatitis B immune globulin and HBV vaccine. J. Infect. Dis. 1985; 151(2): 287-290.
  24. Mazel J.A., Schalm S.W., de Gast B.C., Nuijten A.S., Heijtink R.A., Botman M.J. et al. Passive-active immunization of neonates of HBsAg positive carrier mothers: preliminary observations. Br. Med. J. 1984; 288(6416): 513-515.
  25. Pongpipat D., Suvatte V., Assateerawatts A. Efficacy of hepatitis-B immunoglobulin and hepatitis B vaccine in prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg. Asian Pas. J. Allergy Immunol. 1986; 4(1): 33-36.
  26. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Chitinand S. et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8(Suppl.): 56-59.
  27. Chung W.K., Yoo J.Y., Sun H.S., Lee I.J., Lee I.J., Kim S.M., Prince A.M. Prevention of perinatal transmission of hepatitis B virus: a comparison between the efficacy of passive and passive-active immunization in Korea. J. Infect. Dis. 1985; 151(2): 280-286.
  28. Rybacka-Atamaniuk J. Specific, passive prevention of hepatitis B perinatal transmission to infants born to mothers with HBs antigenemia. Pol. Tyg. Lek. 1991; 46: 268-270.
  29. Lee C.Y., Gong Y., Brok J., Boxall E.H., Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. Br. Med. J. 2006. doi:10.1136/ bmj.38719.435833.7C
  30. Cholingatas E., Papatheodoridis G.V. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J. Gastroenterol. 2013; 19: 9189-9197.
  31. Recommendation of the Advisory Committee on immunization practices (ACIP). A comprehensive immunization strategy to eliminate transmission of Hepatitis B virus infection in the United States. MMVR 2005; 54: RR-16.
  32. Zuckerman J.N. Review: Hepatitis B immune globulin for prevention of Hepatitis B infection. J.Med. Virol. 2007; 79: 919-921.
  33. Герасун Б.А. Пассивная иммунизация нормальным иммуноглобулином для профилактики вирусного гепатита В. Врачебное дело 1981; 7: 109-111.
  34. Голосова Т.В., Марголина А.Н., Сомова А.В., Минакова Л.В. Содержание специфических антител к антигену гепатита В в препаратах иммуноглобулина. Журн.мик-робиол. 1981; 2: 105-106.
  35. Базарова М.В. Клинико-эпидемиологическая оценка эффективности вакцинации против гепатита В новорожденных детей, родившихся у женщин с НВ-вирусной инфекцией. Автореф. дис.. канд. мед. наук. М., 2002.
  36. Казьянин А.В., Ведерникова Н.В., Вязникова Т.В., Пленкина С.В. Изучение фармакодинамики анти-HBs при разных схемах введения препарата АНТИГЕП и вакцины против гепатита В в эксперименте. Материалы Всерос. научн. конф. «Актуальные вопросы вакцинно-сывороточного дела в ХХЇ веке». Пермь, 2003; 86-89.
  37. Казьянин А.В., Пленкина С.В., Николаева А.М., Борисова В.Н., Ведерникова Н.В., Вашин А.Л. Оценка реактогенности отечественного специфического иммуноглобулина человека против гепатита В АНТИГЕП и комбинированной вакцины БУБО-М при иммунизации контактных лиц в очагах. Материалы Всерос. научн. конф. «Актуальные вопросы вакцинносывороточного дела в ХХI веке». Пермь, 2003; 122-125.
  38. Казьянин А.В., Пленкина С.В., Фельдблюм И.В., Борисова В.Н. Сравнительная оценка различных схем иммунизации против гепатита В детей в закрытых организованных коллективах. Пермский медицинский журнал 2004; 2: 103-107.
  39. Казьянин А.В. Стратегия и тактика использования отечественных медицинских иммунобиологических препаратов в системе эпидемиологического контроля за HBV-инфекцией. Автореф. дис.. д-ра мед. наук. Пермь, 2005.
  40. Пленкина С.В. Характеристика очаговости и пути совершенствования экстренной специфической профилактики в очагах острого и хронического гепатита В. Автореф. дис.. канд. мед. наук. Пермь, 2004.
  41. Фельдблюм И.В., Казьянин А.В., Пленкина С.В., Николаева А.М., Борисова В.Н., Гурьянова Н.С. Иммунологическая эффективность симультанной экстренной профилактики в очагах хронического гепатита В при различных схемах иммунизации. В кн.: Достижения отечественной эпидемиологии в ХХ веке. Взгляд в будущее. СПб., 2001. 396 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies